Explore

Trendline Trendline
Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics

Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics

Eli Lilly Expands Pipeline with Acquisition of Kelonia Therapeutics
Trendline Trendline
Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion
Trendline Trendline
Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment

Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment

Eli Lilly to Acquire Kelonia Therapeutics in a $7 Billion Deal to Advance Cancer Treatment
Trendline Trendline
Eli Lilly Plans $2 Billion Acquisition of Kelonia Therapeutics to Expand Cell Therapy Portfolio

Eli Lilly Plans $2 Billion Acquisition of Kelonia Therapeutics to Expand Cell Therapy Portfolio

Eli Lilly Plans $2 Billion Acquisition of Kelonia Therapeutics to Expand Cell Therapy Portfolio
Trendline Trendline
Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion, Enhancing Cancer Cell Therapy Pipeline

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion, Enhancing Cancer Cell Therapy Pipeline

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion, Enhancing Cancer Cell Therapy Pipeline
Trendline Trendline
Eli Lilly Expands Genetic Medicine Portfolio with $7 Billion Acquisition of Kelonia Therapeutics

Eli Lilly Expands Genetic Medicine Portfolio with $7 Billion Acquisition of Kelonia Therapeutics

Eli Lilly Expands Genetic Medicine Portfolio with $7 Billion Acquisition of Kelonia Therapeutics
Trendline Trendline
Eli Lilly Acquires Kelonia Therapeutics for $7 Billion to Enhance CAR T Gene Delivery

Eli Lilly Acquires Kelonia Therapeutics for $7 Billion to Enhance CAR T Gene Delivery

Eli Lilly Acquires Kelonia Therapeutics for $7 Billion to Enhance CAR T Gene Delivery
Trendline Trendline
Eli Lilly Acquires Kelonia Therapeutics to Enhance CAR-T Cell Therapy Development

Eli Lilly Acquires Kelonia Therapeutics to Enhance CAR-T Cell Therapy Development

Eli Lilly Acquires Kelonia Therapeutics to Enhance CAR-T Cell Therapy Development
Reuters Reuters
Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

April 19 (Reuters) - U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday. 
Trendline Trendline
Eli Lilly Acquires Kelonia Therapeutics to Enhance CAR-T Cell Therapy Capabilities

Eli Lilly Acquires Kelonia Therapeutics to Enhance CAR-T Cell Therapy Capabilities

Eli Lilly Acquires Kelonia Therapeutics to Enhance CAR-T Cell Therapy Capabilities
Trendline Trendline
Novo Nordisk Seeks U.S. Market Comeback with Consumer Goods Strategy

Novo Nordisk Seeks U.S. Market Comeback with Consumer Goods Strategy

Novo Nordisk Seeks U.S. Market Comeback with Consumer Goods Strategy
Trendline Trendline
Asahi Kasei Completes Acquisition of Aicuris to Enhance Pharmaceutical Portfolio

Asahi Kasei Completes Acquisition of Aicuris to Enhance Pharmaceutical Portfolio

Asahi Kasei Completes Acquisition of Aicuris to Enhance Pharmaceutical Portfolio